Insider · CIK 0001898147
Enrique Poradosu
Files at NVCT (Nuvectis Pharma, Inc.). First filing Nov 20, 2024, latest Nov 20, 2024.
In brief
Enrique Poradosu files SEC Form 4 as officer at NVCT (Nuvectis Pharma, Inc.). Since Nov 20, 2024, Enrique Poradosu has reported 1 open-market buy worth $9,980 and 0 open-market sells worth $0, the latest filed on Nov 20, 2024.
A track record needs three past buys with six months of prices behind them; Enrique Poradosu has 0, so none is measured yet.
The newest scored trade: bought $9,980 of NVCT on Nov 19, 2024, filed Nov 20, 2024, scored 18 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCT: Nuvectis Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 18Weak | Nuvectis Pharma, Inc. | $9,980 2,000 shares | +0% | - |
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | NVCT Nuvectis Pharma, Inc. | AGrant or award Common Stock | +150,000 | $0.00 | $0 | 1,806,319 | Jan 9, 2026 |
| Nov 19, 2024 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stock | +2,000 | $4.99 | $9,980 | 1,506,319 | Nov 20, 2024 |
Questions about Enrique Poradosu
Answered from the filings on this page, as of the latest one.
Is Enrique Poradosu buying or selling?
Not in the last 12 months. Enrique Poradosu's latest open-market trade on SEC Form 4 was bought $9,980 of NVCT on Nov 19, 2024.
How did Enrique Poradosu's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Enrique Poradosu has 0.
Where does Enrique Poradosu file Form 4?
Enrique Poradosu has filed Form 4 at NVCT (Nuvectis Pharma, Inc.) as Chief Science & Business Off. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.